Abstract: The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-associated diseases, disorders and conditions.

Abstract: The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 ?m, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere.

Abstract: A large-scale K8s cluster monitoring method, an apparatus, a computer device, and a readable storage medium. The method includes: performing classification on data sources in a cluster on the basis of a monitoring metric configuration means, and creating a data list on the basis of the data sources and the monitoring metric configuration means corresponding to said data sources; in response to receiving a command to monitor a first monitoring metric set of a first data source, obtaining a monitoring metric configuration means corresponding to the first data source on the basis of the data list; performing configuration on a monitoring metric on the basis of the first monitoring metric set and by means of the obtained monitoring metric configuration means; and obtaining from the first data source a monitoring metric in the first monitoring metric set every preset amount of time, and performing monitoring on the monitoring metric.

Abstract: The present invention relates to a pharmaceutical composition containing ilaprazole or a salt thereof, and a preparation method therefor. The pharmaceutical composition contains or consists of ilaprazole or a salt thereof, and a ilaprazole derivative, wherein the amount of the ilaprazole derivative in the pharmaceutical composition is not higher than 1.3 wt % (less than or equal to 1.3 wt %). The composition can be used for treating peptic ulcer bleeding and stress ulcer and preventing upper gastrointestinal hemorrhage caused by severe diseases.

Abstract: The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 ?m, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere.